Abstract
In August 2003 the study ?UK Million Women Study (MWS) was published in the journal Lancet and it has excessively stirred up fears over the risk of breast cancer from hormonal treatment. This treatment also included tibolon.
The author revises the relative risk (RR) for breast cancer the study arrived at ? for women without HRT 1.00, the HRT medicated women in the past 1.01, the women taking estrogen monotherapy (women after hysterectomy) 1.30, women with combined estrogen-progesterone therapy 2.00, and women with tibolon 11.45 (1). The year 2004 has brought a number of studies that have specified the approach to tibolon, namely in relation to breast and endometrium, but also to bone metabolism and cardiovascular system.